Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Total Liabilities (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Total Liabilities for 4 consecutive years, with $68.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities fell 64.56% to $68.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $68.4 million, a 64.56% decrease, with the full-year FY2024 number at $191.9 million, up 9.04% from a year prior.
  • Total Liabilities was $68.4 million for Q3 2025 at Century Therapeutics, down from $74.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $194.3 million in Q2 2024 to a low of $68.4 million in Q3 2025.
  • A 4-year average of $158.3 million and a median of $175.9 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: grew 14.6% in 2024, then tumbled 64.56% in 2025.
  • Century Therapeutics' Total Liabilities stood at $183.8 million in 2022, then fell by 4.28% to $175.9 million in 2023, then rose by 9.04% to $191.9 million in 2024, then crashed by 64.36% to $68.4 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Total Liabilities are $68.4 million (Q3 2025), $74.8 million (Q2 2025), and $75.2 million (Q1 2025).